A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure.

A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

Epigenetic changes in Wilms tumor, a rare type of childhood kidney cancer, do not appear to be widespread.

A new way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue - a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients.

Researchers from the Keck School of Medicine of the University of Southern California (USC) found that patients who received a later stage cancer diagnosis were likely to be living in an unsafe neighborhood, using public transportation and traveling at least 45 minutes to get to a doctor's office. The study will be presented at this week's American Association of Cancer Research (AACR) in Los Angeles on April 15.

Sutent (sunitinib malate) has received a European Association of Urology (EAU) recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma (mRCC).